Jyong Biotech Ltd. Ordinary Shares (MENS)
Automate Your Wheel Strategy on MENS
With Tiblio's Option Bot, you can configure your own wheel strategy including MENS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MENS
- Rev/Share 0.0
- Book/Share -0.4803
- PB -112.9204
- Debt/Equity -0.4966
- CurrentRatio 0.017
- ROIC -1.2238
- MktCap 4026433935.0
- FreeCF/Share -0.0477
- PFCF -1111.0469
- PE -1365.9293
- Debt/Assets 2.8487
- DivYield 0
- ROE 0.0855
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)
Published: August 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
New Taipei City, Taiwan, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, announced its participation in the 22nd Urological Association of Asia Congress which was held in conjunction with the 47th Annual Meeting of the Taiwan Urological Association on August 14–17, 2025, and exhibited topline results from the multiple clinical studies of …
Read More
Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention
Published: July 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
New Taipei City, Taiwan, July 22, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, announced completion of its Nasdaq IPO ceremony, and that it participated at the world's largest biotechnology exhibition BIO 2025 International Convention, where it engaged with other global pharmaceutical companies.
Read More
U.S. IPO Weekly Recap: Sizable Precision Medicine And Insurance IPOs Raise A Combined $902 Million
Published: June 22, 2025 by: Seeking Alpha
Sentiment: Positive
A handful of IPOs and blank checks priced in the short holiday week, led by two sizable issuers. Two smaller IPOs also priced this past week. One IPO is currently scheduled to list in the week ahead, although some small names may also join the calendar throughout the week.
Read More
About Jyong Biotech Ltd. Ordinary Shares (MENS)
- IPO Date 2025-06-17
- Website https://www.jyongbio.com/
- Industry Biotechnology
- CEO Kuo Fu-Feng
- Employees 31